Anastrozole vs. Tamoxifen in Early Breast Cancer: A Long-Term Update
After 5 years of therapy and 3 years of follow-up, disease recurrence was diminished by anastrozole, but overall mortality was the same in the two groups.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)